The Screen Failure You Can Prevent Before the Patient Leaves Home
Mayo Test Drive completed at 97.5% across MCI, mild, and moderate dementia patients, here's what that means for Alzheimer's...
Medpace Expands Phase I Unit With On-Site Imaging and Specialized Assessments
Medpace expands Phase I Unit with on-site imaging and specialized assessments to reduce participant dropout and keep trial endpoints...
RBQM vs. RBDM: Data Teams Must Link Quality Plans to Management Protocols
Risk-based quality management requires linking quality plans to data management protocols. EU regulators now expect documented traceability between RBQM...
Coya Therapeutics Enrolls 100th Patient in ALSTARS Trial of COYA 302 for ALS
Coya Therapeutics enrolls 100th patient in ALSTARS trial of COYA 302 for ALS, reaching a key recruitment milestone for...
BH-30643 achieves 45% response rate in osimertinib-resistant NSCLC patients
BH-30643 achieves 45% response rate in osimertinib-resistant NSCLC patients with C797S mutations, showing 88% disease control in Phase 1/2...
Summit Therapeutics Presents Updated Overall Survival Data for Ivonescimab in EGFR-Mutated NSCLC
Summit Therapeutics presents updated overall survival results for ivonescimab in EGFR-mutated NSCLC from the Phase III HARMONi trial.
Roche’s Lunsumio combo meets primary endpoint in Phase III follicular lymphoma trial
Roche's Lunsumio combo met its primary endpoint in Phase III follicular lymphoma trial, beating rituximab plus lenalidomide on progression-free...
“Hard to Reach” Is a Sponsor Operations Failure, Not a Population Problem
The Lancet calls out "hard to reach" as a stigmatizing label. For clinical ops, it's a site selection failure...
Benchmark Scores Don’t Save Patients: Why Clinical AI Needs RCT-Grade Evidence Before It Touches a Workflow
Med-Gemini scores 91% on MedQA. OpenAI's o1-preview hits 96%. Neither number tells you what happens when the algorithm meets...